• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Iconovo

1.15 SEK

-0.43 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.43 %
+1.77 %
+0.44 %
+0.88 %
0.00 %
-42.50 %
-95.72 %
-98.43 %
-96.47 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
110.6M SEK
Turnover
139.68K SEK
Revenue
1.11M
EBIT %
-3,883.78 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

23/10
2026

Interim report Q3'26

26/2
2027

Annual report '26

Press release21 hours ago

Iconovo och Lonza ingår strategiskt samarbetsavtal

Iconovo
Press release21 hours ago

Iconovo and Lonza sign Strategic Collaboration Agreement

Iconovo
Regulatory press release5/28/2026, 12:00 PM

Kommuniké från årsstämma i Iconovo AB den 28 maj 2026

Iconovo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release4/24/2026, 3:52 PM

DNB Carnegie Access: Iconovo: Limited progress – Q1 review

Iconovo
Regulatory press release4/24/2026, 7:00 AM

Kallelse till årsstämma i Iconovo AB

Iconovo
Regulatory press release4/24/2026, 6:30 AM

KVARTALSRAPPORT Q1 2026

Iconovo
Regulatory press release4/24/2026, 6:30 AM

QUARTERLY REPORT Q1 2026

Iconovo
Regulatory press release4/23/2026, 2:40 PM

ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2025

Iconovo
Regulatory press release4/14/2026, 1:40 PM

Anders Månsson utsedd till Verkställande Direktör

Iconovo
Regulatory press release4/14/2026, 1:40 PM

Anders Månsson is appointed CEO

Iconovo
Regulatory press release3/17/2026, 3:05 PM

Iconovo offentliggör utfall av inlösen av teckningsoptioner serie TO 1

Iconovo
Regulatory press release3/17/2026, 3:05 PM

Iconovo publishes outcome of exercise of warrants series TO 1

Iconovo
Regulatory press release3/10/2026, 7:05 AM

Iconovos företrädesemission har registrerats – omvandling av BTA till aktier

Iconovo
Regulatory press release3/10/2026, 7:05 AM

Iconovo’s rights issue is registered – conversion of BTA into shares

Iconovo
Regulatory press release3/2/2026, 3:20 PM

Iconovo offentliggör slutligt utfall i företrädesemissionen

Iconovo
Regulatory press release3/2/2026, 3:20 PM

Iconovo announces final outcome in the rights issue

Iconovo
Regulatory press release2/27/2026, 5:20 PM

Iconovo offentliggör preliminärt utfall i företrädesemission och meddelar omräkning av teckningsoptioner serie TO 1

Iconovo
Regulatory press release2/27/2026, 5:20 PM

Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1

Iconovo
Press release2/24/2026, 7:50 PM

Iconovo och Lonza ingår avsiktsförklaring gällande strategiskt samarbete

Iconovo
Press release2/24/2026, 7:50 PM

Iconovo and Lonza signs LOI regarding strategic collaboration

Iconovo